INTRODUCTION {#s1}
============

Pancreatic cancer is one of the most lethal and aggressive of all malignancies and the fourth leading cause of death in the developed countries \[[@R1]\]. Currently, chemotherapy with gemcitabine and nab-paclitaxel (GN) is recommended for locally advanced unresectable and metastatic pancreatic cancer. However, the median overall survival remains unsatisfactory with 8.5 months \[[@R2], [@R3]\].

Immunomodulatory drugs (IMiDs) have been considered as effective agents for treatment of colorectal \[[@R4], [@R5]\], lung \[[@R6]\], and prostate cancers \[[@R7]\]. The detailed mechanism by which IMiDs induce apoptosis in solid tumors remains unclear. Pomalidomide (PMD) is a third-generation IMiD derived from thalidomide and has antiproliferative effects on hematological malignancies \[[@R8]\]. Similar to thalidomide, PMD has direct antiproliferative, pro-apoptotic, and antiangiogenetic effects on multiple myeloma cells, as well as modulatory effects on the immune system \[[@R8]--[@R10]\].

IMiDs modulate serum levels of inflammatory cytokines and growth factors, such as IL-6, IL-12, IL-8 and granulocyte-macrophage colony-stimulation factor (GM-CSF), which contribute to cancer progression and antitumor immunity \[[@R11]\]. IMiDs enhance the cancer suppressing effect of natural killer (NK) and CD8+ cells by increasing IL-2 levels \[[@R12]\] and by suppression of T regulatory (T-reg) cell \[[@R13]\]. Moreover, IMiDs, including PMD, have been reported to have antitumor effect through induction of apoptosis \[[@R8]\], cell cycle arrest \[[@R14]\] and suppression of angiogenesis \[[@R15]\] in hematological malignancies. PMD has an immunosuppressive effect 15,000 to 50,000 times more potent than thalidomide and 10-fold more potent than lenalidomide on inhibition of tumor necrosis factor (TNF-α) \[[@R8], [@R16]\]. Therefore, PMD is expected to have more potent antitumor activity as compared to thalidomide or lenalidomide in digestive cancer. In the past clinical trial, the combination of gemcitabine with lenalidomide showed no significant difference as compared to gemcitabine alone \[[@R17]\] on pancreatic cancer. However, considering the strength of the effects of pomalidomide, we believe that GNP therapy is expected to have a stronger effect than the combination of gemcitabine with lenalidomide.

Furthermore, PMD directly induces caspase-8-dependent apoptosis and inhibits nuclear factor-kappaB (NF-κB) transcriptional activity \[[@R18], [@R19]\]. NF-κB positively acts on the proliferation of digestive cancers through expression of VEGF \[[@R20], [@R21]\], inhibition of apoptosis proteins (IAPs) \[[@R22]--[@R24]\], and induction of chemoresistance \[[@R25]--[@R27]\]. Therefore, suppression of NF-κB activation is important to improve chemo-susceptibility. Also, PMD induces cell cycle arrest at the G0/G1 phase in multiple myeloma cells \[[@R14]\]. However, these effects and mechanisms remain unverified in solid tumors.

The purpose of this study is to investigate the antitumor effect and to clarify the mechanisms of PMD in pancreatic cancer.

RESULTS {#s2}
=======

PMD suppressed the activation of nuclear NF-κB *in vitro* {#s2_1}
---------------------------------------------------------

To evaluate the activation of NF-κB in pancreatic cancer cell lines, the concentration of p65 in the nuclear extracts were measured using ELISA, and IκBα levels were evaluated using Western blot analysis. The concentrations of NF-κB p65 in the nuclear extracts of PANC-1 and MIA PaCa-2 in the GN group (GN group means cells treated with GN) were significantly greater than those in the C group (*p* \< 0.01) (C group means cells treated with vehicle), whereas those in the GNP group (GNP group means cells treated with GNP) were significantly lower than those in the GN group (*p* \< 0.01). In MIA PaCa-2 cells, the concentrations of NF-κB p65 in the nuclear extracts in the P group were significantly lower than that in the C group (*p* \< 0.01, Figure [1A](#F1){ref-type="fig"}) (P group means cells treated with PMD alone). Similar to nuclear NF-κB concentrations, IκBα levels of PANC-1 and MIA PaCa-2 in the P group were greater than those in the C group, whereas phosphorylated IκBα levels of PANC-1 and MIA PaCa-2 in the GNP group were lower than those in the GN group (Figure [1B](#F1){ref-type="fig"}).

![(**A**) The activation of NF-κB was measured using ELISA at 2 hours after each treatment. The concentrations of NF-κB p65 in the nuclear extracts of PANC-1 and MIA PaCa-2 in GN group were significantly greater than those in C group (PANC-1, *p* \< 0.01; MIA PaCa-2, *p* \< 0.01), whereas those in GNP group were significantly lower than those in GN group (PANC-1, *p* \< 0.01; MIA PaCa-2, *p* \< 0.01). (**B**) Similar to nuclear NF-κB concentrations, IκBα levels of PANC-1 and MIA PaCa-2 in P group were greater than those in C group, whereas phosphorylated IκBα levels of PANC-1 and MIA PaCa-2 in GNP group were lower than those in GN group at 2 hours after treatment.](oncotarget-09-15780-g001){#F1}

PMD enhanced antitumor effects and induced apoptosis {#s2_2}
----------------------------------------------------

To evaluate the antitumor effect of PMD in pancreatic cancer, we examined cell viability and apoptotic cells. In the cell proliferation assay, the viability of MIA PaCa-2 cells was significantly decreased by PMD monotherapy (46.9 ± 6.2% vs. 100 ± 17.0%, *p* \< 0.01) and the viabilities in the GNP group of PANC-1 and MIA PaCa-2 were significantly lower than those in the GN group (PANC-1, 67.0 ± 1.6% vs. 83.2 ± 4.3%, *p* \< 0.01; MIA PaCa-2: 35.5 ± 8.3% vs. 64.8 ± 7.9%, *p* \< 0.01, Figure [2A](#F2){ref-type="fig"}). In the apoptosis analysis, the apoptotic cells in the GNP group of PANC-1 and MIA PaCa-2 were significantly greater than those in the GN group (PANC-1, 77.1 ± 0.9% vs. 72.0 ± 1.3%, *p* \< 0.01; MIA PaCa-2, 10.0 ± 1.1% vs. 6.44 ± 1.2%, *p* \< 0.05, respectively, Figure [2B](#F2){ref-type="fig"}). To investigate more details of the molecular mechanism by which PMD induced apoptosis, the apoptotic signals were evaluated using Western blot analysis. The levels of p53, cleaved caspase-8 and -3 as well as cleaved PARP in the GNP group were greater than those in the GN group (Figure [2C](#F2){ref-type="fig"}).

![(**A**) Cell viabilities of PANC-1 and MIA PaCa-2 cells were shown as the percent of control at 72 hours (PANC-1) and 48 hours (MIA PaCa-2) after treatment. In the cell proliferation assay, the viability in GNP group of PANC-1 and MIA PaCa-2 was significantly lower than that in GN group (PANC-1, *p* \< 0.01; MIA PaCa-2, *p* \< 0.01). (**B**) The proportion of early and late apoptotic cells was evaluated by Annexin/FITC analysis at 72 hours (PANC-1) and 48 hours (MIA PaCa-2) after treatment. The apoptotic cells in GNP group of PANC-1 and MIA PaCa-2 were significantly greater than those in GN group (PANC-1, *p* \< 0.01; MIA PaCa-2, *p* \< 0.05). (**C**) Western blot analysis demonstrated the expression of proteins related to apoptosis. After 2 hours treatment with PMD, gemcitabine and nab-paclitaxel were administered. PANC-1 and MIA PaCa-2 cells were harvested at 72 hours and 48 hours after treatment, respectively. The levels of p53, cleaved caspase-8 and -3 as well as cleaved PARP in GNP group were greater than those in GN group.](oncotarget-09-15780-g002){#F2}

*In vivo* analysis {#s2_3}
------------------

The tumor growth in the GNP group was significantly slower than that in the GN group (Figure [3A](#F3){ref-type="fig"}). Both tumor weights and volume of the excised tumor in the GNP group were significantly lower than those in GN group (weight, 385.3 ± 88.2 mg vs. 538.6 ± 36.2 mg, *p* \< 0.05; volume, 0.36 ± 0.02 cm^3^ vs. 0.76 ± 0.04 cm^3^, *p* \< 0.01, respectively, *n* = 4 for each, Figure [3B](#F3){ref-type="fig"}). In contrast, there was no difference in the change in body weight among the treatment groups (Figure [3C](#F3){ref-type="fig"}). In the GNP group, the number of Ki-67-positive cells in the excised tumor was significantly lower than that in the GN group (40.7 ± 3.2 vs. 63.3 ± 7.7 %, *p* \< 0.01). Additionally, the number of Ki-67-positive cells in the P group was significantly lower than that in the C group (67.1 ± 2.4% vs. 74.8 ± 3.8%, *p* \< 0.05, Figure [3D](#F3){ref-type="fig"}). The TUNEL assay of the excised tumor showed that the number of apoptotic cells in the GNP group was significantly greater than that in the GN group (107 ± 2.6 vs. 63.0 ± 1.0, *p* \< 0.01, Figure [3E](#F3){ref-type="fig"}).

![(**A**) T2-weighted MRI detected tumors in the tail of the pancreas on the left side of the body. MRI revealed that tumor growth in GNP group was slower than that in GN group (*p* \< 0.05). (**B**) At five weeks after treatment, both tumor weight and volume of excised tumor in GNP group were significantly lower than those in GN group (weight, *p* \< 0.05; volume, *p* \< 0.01) (*n* = 4 each). (**C**) Body weight changes during the treatment. There was no difference in the change in body weight among the experimental groups. (**D**) In GNP group, the number of Ki-67-positive cells in the excised tumor was significantly lower than that in GN group (*p* \< 0.01). The number of Ki-67-positive cells in P group was significantly lower than that in C group (*p* \< 0.05) (×400). (**E**) The TUNEL assay of the excised tumor showed that the number of apoptotic cells in GNP group was significantly greater than that in GN group (*p* \< 0.01) (×400).](oncotarget-09-15780-g003){#F3}

NF-κB activation in the excised tumor was assessed using ELISA, and IκBα levels were evaluated using Western blot analysis. The concentrations of NF-κB p65 in the excised tumor in the GN group were significantly greater than those in the C group (*p* \< 0.05), whereas those in the GNP group were significantly lower than those in the GN group (*p* \< 0.05, Figure [4A](#F4){ref-type="fig"}). Similar to nuclear NF-κB concentrations, IκBα levels in the P group were greater than those in the C group, whereas phosphorylated IκBα levels in the GNP group were lower than those in the GN group, as observed in the *in vitro* experiments (Figure [4B](#F4){ref-type="fig"}). Similar to the *in vitro* experiments, the level of p53, cleaved caspase-8 and 3 as well as cleaved PARP in the GNP group were greater than those in the other groups (Figure [4C](#F4){ref-type="fig"}).

![(**A**) The concentrations of NF-κB p65 in the excised tumor in GN group were significantly greater than those in C group (*p* \< 0.05), whereas those in GNP group were significantly lower than those in GN group (*p* \< 0.05). (**B**) Similar to nuclear NF-κB concentrations, IκBα levels in P group were greater than those in C group, whereas phosphorylated IκBα levels in GNP group were lower than those in GN group, as observed in the *in vitro* experiments. (**C**) Similar to the *in vitro* experiments, the level of p53, cleaved caspase-8 and 3 as well as cleaved PARP in GNP group were greater than those in the other groups.](oncotarget-09-15780-g004){#F4}

G0/G1 cell cycle arrest {#s2_4}
-----------------------

To evaluate the effect of PMD on cell cycle progression in pancreatic cancer cells, we performed cell cycle analysis using flow cytometry. The proportion of cells in the G0/G1 phase in the P group was greater than that in the C group (PANC-1, 74.0 ± 1.0% vs. 66.3 ± 1.0%, *p* \< 0.01; MIA PaCa-2, 54.2 ± 1.4% vs. 48.6 ± 2.2%, *p* \< 0.01, Figure [5A](#F5){ref-type="fig"}). Additionally, the expression levels of phosphorylated Rb, which plays an important role in cell cycle progression \[[@R28], [@R29]\] was examined. The level of phosphorylated Rb (Ser 780) protein in the P group was lower than that in the C group for PANC-1 and MIA PaCa-2 (Figure [5B](#F5){ref-type="fig"}). In this experiment, it was not appropriate to correctly evaluate the influence of PMD on GN with flow cytometry because GN also influence on cell cycle. Therefore, we simply examined the effect of PMD on pancreatic cancer cells.

![(**A**) The proportion of cells in the G0/G1 phase in P group was greater than that in C group (PANC-1, *p* \< 0.01; MIA PaCa-2, *p* \< 0.01). (**B**) The level of phosphorylated Rb (Ser 780) protein in P group was lower than that in C group for both PANC-1 and MIA PaCa-2 cells.](oncotarget-09-15780-g005){#F5}

PMD inhibited angiogenesis in pancreatic cancer cells {#s2_5}
-----------------------------------------------------

To investigate detailed molecular mechanism of antitumor effect by PMD, the expression of VEGF, which plays an important role in angiogenesis and is a target molecule of NF-κB was measured. The levels of VEGF protein in the GNP group were lower than those in the GN group, both *in vitro* and *in vivo* (Figure [6A](#F6){ref-type="fig"}). Immunohistochemical staining of the excised tumors showed that the number of VEGF-positive cells in the GNP group was fewer than that in the GN group (Figure [6B](#F6){ref-type="fig"}). The angiogenesis assay was performed to evaluate the effect of PMD on endothelial cell tube formation in PANC-1 and MIA PaCa-2. The number of connected cells in the P group was significantly fewer than that in the C group (PANC-1, 7.1 ± 1.3 vs. 12.5 ± 1.3, *p* \< 0.01; MIA PaCa-2, 8.4 ± 0.6 vs. 11.8 ± 1.6, *p* \< 0.05, respectively, Figure [6C](#F6){ref-type="fig"}). This experiment was not suitable for comparing GN and GNP group because all the cells in both GN group and GNP group were separated with each other. Therefore, we compared C group and P group.

![(**A**) The levels of VEGF in GNP group were lower than those in GN group, both *in vitro* and *in vivo.* (**B**) Immunohistochemical staining of excised tumors showed that the number of VEGF-positive cells in GNP group was fewer than those in GN group (×400). (**C**) The *in vitro* angiogenesis assay revealed the number of connected cells in P group was significantly fewer than that in C group (PANC-1, *p* \< 0.01; MIA PaCa-2, *p* \< 0.05) (×200).](oncotarget-09-15780-g006){#F6}

DISCUSSION {#s3}
==========

Recently, combination chemotherapy with gemcitabine and nab-paclitaxel has been demonstrated to be effective for unresectable pancreatic cancer \[[@R30]--[@R32]\]. However, antitumor drug-induced NF-κB activation is considered to reduce chemosensitivity thorough various inflammation-related gene transcription \[[@R33]\]. Therefore, suppression of agent-induced NF-κB activation could be a new therapeutic approach to improve chemosensitivity \[[@R22], [@R23], [@R25], [@R32], [@R34]--[@R36]\].

In the current study, GN decreased IκBα and enhanced NF-κB activation, whereas PMD suppressed phosphorylation of IκBα and inhibited the NF-κB activation. Moreover, PMD had dual apoptotic effect of enhancing p53 and cleaved caspase-8-dependent pathway on pancreatic cancer. To the best of our knowledge, we firstly demonstrated enhancement of p53, which directly activates the transcription of apoptotic genes \[[@R37], [@R38]\] by PMD on pancreatic cancer.

PMD is also known to induce G0/G1 phase cell cycle arrest \[[@R14]\]. The pRb regulates the local chromatin structure by recruiting histone deacetylase 1 (HDAC1) to modulate the balance of histone acetylation levels. The pRb blocks cell cycle progression by repressing E2F-target gene transcription through the recruitment of transcriptional corepressors and chromatin remodeling protein factors, such as HDACs, Sin3, CtBP and SWI/SNF, at promoter regions \[[@R28]\]. Hypophosphorylated pRb binds to DNA-bound E2F transcriptional regulators and suppresses their target gene expression through the recruitment of HDACs, co-repressors and chromatin remodeling enzymes. When it is in a hyperphosphorylated state, the complex is dissociated, and the cell cycle progresses \[[@R39], [@R40]\]. In the current study, we firstly demonstrated that PMD inhibited the Ser^780^ phosphorylation of pRb and caused G0/G1 cell cycle arrest. These result suggested that PMD contributed to G0/G1 cell cycle arrest via the pRb pathway in pancreatic cancer cells.

The importance of angiogenesis in cancer progression has been demonstrated in various cancers \[[@R41]\]. VEGF is downstream of NF-κB signal transduction and is known to play a key role in neovascularization \[[@R42], [@R43]\]. In the current study, we have shown that the level of VEGF was decreased and neovascularization was suppressed by PMD. Regarding solid tumor, previous report has also described that IMiDs inhibit angiogenesis in gastric cancer \[[@R44]\].

PMD has a manageable toxicity profile in patients who relapsed after multiple types of therapy for myeloma \[[@R45]\]. The most common grade 3 or 4 hematologic side effect is neutropenia, while non-hematologic grade 3 or 4 adverse effects are fatigue and pneumonia \[[@R8]\]. Grades 3 and 4 adverse events were reported in more than 5% of patients in the phase II clinical trials for PMD/dexamethasone for multiple myeloma \[[@R8]\]. Our *in vivo* study showed no significant body weight differences or treatment-related deaths. This indicated that current regimen does not have nutrition-related disadvantages.Nevertheless, another *in vivo* study using PMD shown thrombocytosis in combination with gemcitabine and S-1, therefore we must keep in mind checking platelet count in clinical use.

In summary, PMD enhanced the antitumor effects of GN by inhibiting NF-κB activation. PMD induced caspase-8-mediated apoptosis, enhancement of p53, cell cycle arrest, and antiangiogenesis. Therefore, PMD with GN therapy may be a novel treatment with strong antitumor effect on pancreatic cancer.

MATERIALS AND METHODS {#s4}
=====================

Cell culture {#s4_1}
------------

The human pancreatic cancer cell lines PANC-1 and MIA PaCa-2 were purchased from the American Type Culture Collection (ATCC, Rockville, MD). PANC-1 and MIA PaCa-2 were guaranteed by ATCC, and maintained in Dulbecco's modified Eagle's Medium (D-MEM) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) containing 10% fetal bovine serum (Gibco, Grand Island, NY) and 1% penicillin/streptomycin (Gibco/Brl). The cells were cultured at 37° C with 5% CO~2~.

Reagents {#s4_2}
--------

PMD was purchased from Tokyo Chemical Industry (Tokyo, Japan) and was dissolved in 1% dimethyl sulfoxide (DMSO) and stored at −80° C until use. Gemcitabine was purchased from Eli Lilly Japan (Kobe, Japan). Nab-paclitaxel was purchased from Taiho Pharmaceutical Co. Ltd (Tokyo, Japan).

Antibodies {#s4_3}
----------

Monoclonal antibodies to inhibitor of kappaBα (IκBα), cleaved caspase-3 and -8, and cleaved poly-ADP-ribose polymerase (PARP) were purchased from Cell Signaling Technology (Beverly, MA). Anti-b-actin antibody was purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal antibodies against p53 (DO-1) and VEGF (A-20) were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Anti-Rb (phospho-Ser 780) antibody was purchased from Abcam (Cambridge, UK). Monoclonal anti-Ki-67 antibody (MIB-1) was purchased from Dako (Glostrup, Denmark).

Animals {#s4_4}
-------

Five-week-old male nude mice (BALBc nu/nu) were purchased from CLEA Japan, Inc, (Tokyo, Japan) and housed under specific pathogen-free conditions in a biological cabinet at the Laboratory Animal Facility of the Jikei University School of Medicine. The protocol for the animal experiments was approved by the Institutional Animal Care and Use Committee of Jikei University (no. 2015--002) and fulfilled the Guidelines for the Proper Conduct of Animal Experiments of the Science Council of Japan (2006). All the guidelines above are based on the Declaration of Helsinki.

*In vitro* experimental protocol {#s4_5}
--------------------------------

PANC-1 and MIA PaCa-2 cells were treated in 4 conditions: pomalidomide (100 μM; P group), gemcitabine (1000 nM and 494 nM, respectively) and nab-paclitaxel (500 nM and 683 nM, respectively) (GN group), gemcitabine and nab-paclitaxel with pomalidomide (GNP group), or vehicle only (1% DMSO; C group) for the appropriate time in each analysis. The concentrations of gemcitabine and nab-paclitaxel were determined according to the previous studies \[[@R30], [@R32]\]. The appropriate doses were determined with reference to the IC50 and different concentrations of experiments we performed. In the GNP group, the cells were treated with PMD for 2 hours before the administration of gemcitabine and nab-paclitaxel.

*In vivo* experimental animal model and protocol {#s4_6}
------------------------------------------------

The orthotopic pancreatic cancer mice model was used as previously described \[[@R32], [@R46]\]. The mice were continuously anesthetized with 2% isoflurane (Pfizer Japan Inc., Tokyo, Japan), and a 5-mm incision was made in the left flank on the splenic silhouette. The distal pancreas was gently delivered from the peritoneal cavity with spleen thorough the incision. 5.0 × 10^6^ PANC-1 cells suspended in 40 µl of phosphate buffered saline (PBS) were injected into the tail of the pancreas. After injection, the pancreas was placed in the abdomen and the abdominal wound site was closed in two layers. At 4 weeks after the injection, the animals were randomly divided into four treatment groups, which were the same as the *in vitro* experimental groups (*n* = 4). Pomalidomide (0.5 mg/kg) was administered orally five times a week, and gemcitabine (50 mg/kg) and nab-paclitaxel (0.5 mg/kg) were injected intraperitoneally once a week. The doses of antitumor agents were determined according to the previous studies \[[@R32], [@R47]\]. In the C group, vehicle of pomalidomide (PBS) was administered orally five times a week, which vehicles of gemcitabine and nab-paclitaxel (distilled water and isotonic sodium, respectively) were injected intraperitoneally once a week. The tumor volume was evaluated sequentially once a week by magnetic resonance imaging (MRI). At five weeks after treatment, the animals were sacrificed and orthotopic pancreatic tumors were excised for the assessment.

MRI *in vivo* protocol {#s4_7}
----------------------

The animals were imaged in the prone position inside a clinical 9.4 T MRI System (BioSpin 94/20 USR, Bruker, Ettingen, Germany) using a coronal multi-slice T2-weighted protocol (TurboRARE-T2) (Paravision 5.1; PV5.1, Bruker).

Quantitative analysis of NF-κB activity {#s4_8}
---------------------------------------

NF-κB is typically a heterodimer consisting of the p65 and p50 proteins, and it normally resides in the cytoplasm as an inactivate form as a complex with an IκBα. NF-κB activation signals lead to IκBα phosphorylation, and NF-κB is released from IκBα, and then translocated into the nucleus. Nuclear extracts from both *in vitro* and *in vivo* experiments were prepared using a nuclear extract kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions. The nuclear extracts were assayed using an enzyme-linked immunosorbent assay (ELISA) kit (Trans-AM NF-κB p65 Activation Assay; Active Motif) to detect and quantify the NF-κB p65 activity according to the manufacturer's instructions. The levels of NF-κB p65 were measured at 2 hours after treatment.

Western blot analysis {#s4_9}
---------------------

Whole protein extracts from both *in vitro* and *in vivo* experiments were prepared according to the protocol described previously \[[@R48]\]. The lysate protein was extracted by 2% sodium dodecyl sulfate, electrophoresed on 4% to 20% acrylamide gradient gels in Tris-glycine buffer, and transferred onto a nitrocellulose membrane. After incubating the blots in each primary antibody (1:1000 dilution) overnight, the membranes were then incubated with secondary antibody (1:10,000 dilution, Histofine; Nichirei, Tokyo, Japan). A luminol enhancer and peroxide solution, Clarity Max (Bio-Rad Laboratories, Inc., Hercules, CA), was used to detect the protein bands. Protein bands were detected using a Chemi Doc XRS+ system and evaluated using Image Lab software (Bio-Rad).

Cell proliferation assay {#s4_10}
------------------------

The cells were seeded into 96-well plates (5 × 10^3^ cells/well) and treated for 72 hours (PANC-1) or 48 hours (MIA PaCa-2). The cell proliferation was measured using a CellTiter-Blue Cell Viability Assay Kit (Promega, Madison, WI) according to the manufacturer's instructions. The stained cells were analyzed with a PerkinElmer EnSpire plate reader (PerkinElmer Inc., Waltham, MA).

Assessment of apoptosis by flow cytometry {#s4_11}
-----------------------------------------

The cells (1 × 10^6^ cells) were seeded and treated with each regimen for 72 hours (PANC-1) or 48 hours (MIA PaCa-2). These cells were washed with 1× binding buffer and incubated with 10 µl of Annexin V/FITC (Annexin V/FITC Kit; Miltenyi Biotec GmbH, Cologne, Germany) for 15 minutes in the dark at room temperature. The stained cells were analyzed with an Attune NxT Flow Cytometer (Thermo Fisher Scientific, Waltham, MA).

Cell cycle analysis {#s4_12}
-------------------

The cells were harvested after treatment for 72 hours (PANC-1) or 48 hours (MIA PaCa-2) and were fixed in 70% ethanol for 30 minutes at −20° C. After centrifugation, the cell pellets were washed with PBS and incubated at room temperature for 1 minute, followed by incubation with RNase (1 µg/ml) for 4 minutes. Finally, these cells were incubated with propidium iodide (1 mg/ml) (Sigma-Aldrich, St Louis, MO) for 30 minutes. DNA content was determined with an Attune NxT Flow Cytometer (Thermo Fisher Scientific).

*In vitro* angiogenesis assay {#s4_13}
-----------------------------

To evaluate the antiangiogenic effect of PMD in pancreatic cancer, an *in vitro* angiogenesis assay kit (Trevigen Inc., Gaithersburg, MD) was used. Pancreatic cell lines were seeded into 96-well plates (5 × 10^3^ cells/well) on top of an aliquot of 50 µl of basement membrane. These cells were incubated with PMD for 24 hours and fixed with 3.7% methanol. These cells were continuously stained with cell staining solution according to the manufacturer's instructions. This assay evaluates the ability of the cells to connect. The number of intersections was counted in three random fields per well for three wells. This experiment was conducted with reference to \[[@R49]\].

Immunohistochemical staining {#s4_14}
----------------------------

Paraffin sections of tumor tissues were stained immunohistochemically using anti-Ki-67 and VEGF antibodies as the primary antibodies and the DAKO Envision Kit/HRP as a secondary antibody (DAKO, Carpenteria, CA). A TdT-mediated dUTP nick end labeling (TUNEL) assay was performed using an *In Situ* Cell Death Detection Kit with fluorescein (Roche Diagnostics, Basel, Switzerland) to evaluate the induction of apoptosis. These measurements were performed according to the manufacturer's instructions. The number of Ki-67-positive cells and TUNEL-positive cells were counted in three random fields (×400 and ×200, respectively) in three tumors.

Statistical analysis {#s4_15}
--------------------

Data are expressed as the mean ± SD. Non-paired t-test (2-tailed) and repeated measurements analysis (ANOVA) of variance were used for statistical analysis with SPSS 23.0 (IBM Japan, Tokyo, Japan). All *p* values were considered statistically significant when the associated probability was \< 0.05.
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